Frontiers in neuroscience · 2024
The identification of cognitive impairment in Parkinson's disease using biofluids, neuroimaging, and artificial intelligence.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dennis Anthaea-Grace Patricia, Strafella Antonio P
Аннотация
INTRODUCTION: Parkinson's disease (PD) is a neurodegenerative movement disorder causing severe disability and cognitive impairment as the disease progresses. It is necessary to develop biomarkers for cognitive decline in PD for earlier detection and prediction of disease progression.
METHODS: We reviewed literature which used artificial intelligence-based techniques, which can be more sensitive than other analyses, to determine potential biomarkers for cognitive impairment in PD.
RESULTS: We found that combining biomarker types, including those from neuroimaging and biofluids, resulted in higher accuracy. Focused analysis on each biomarker type revealed that using structural and functional magnetic resonance imaging (MRI) resulted in accuracy and area under the curve (AUC) values above 80%/0.80, and that beta-amyloid-42 and tau were able to classify PD subjects by cognitive function with accuracy and AUC values above 90%/0.90.
DISCUSSION: We can conclude that applying both blood-based and imaging-based biomarkers may improve diagnostic accuracy and prediction of cognitive impairment in PD.
METHODS: We reviewed literature which used artificial intelligence-based techniques, which can be more sensitive than other analyses, to determine potential biomarkers for cognitive impairment in PD.
RESULTS: We found that combining biomarker types, including those from neuroimaging and biofluids, resulted in higher accuracy. Focused analysis on each biomarker type revealed that using structural and functional magnetic resonance imaging (MRI) resulted in accuracy and area under the curve (AUC) values above 80%/0.80, and that beta-amyloid-42 and tau were able to classify PD subjects by cognitive function with accuracy and AUC values above 90%/0.90.
DISCUSSION: We can conclude that applying both blood-based and imaging-based biomarkers may improve diagnostic accuracy and prediction of cognitive impairment in PD.